PVRIG/CD112R Full-Length Nanodisc Proteins, and Flow Antibodies

Poliovirus Receptor-Related Immunoglobulin Domain (PVRIG), also known as CD112R, is an inhibitory immunoglobulin-superfamily receptor expressed primarily on T cells and NK cells. Its major ligand is PVRL2/Nectin-2 (CD112). Engagement of PVRIG by CD112 suppresses T-cell receptor-associated signaling and immune-cell effector function. This pathway intersects with the TIGIT–CD155/CD112 and CD226-CD155/CD112 networks, creating a broader regulatory system that balances activating and inhibitory signals in T and NK cells. Because PVRIG competes with the costimulatory receptor CD226 for CD112 and can be co-expressed with other inhibitory receptors in tumors, it has emerged as a next-generation immune-checkpoint target. Candidate antibodies are therefore commonly evaluated for CD112 blocking, cellular binding, and restoration of T/NK-cell function.

DIMA BIOTECH provides full human PVRIG ECD and a 53–150 fragment for ELISA, PVRIG-CD112 interaction studies, antibody screening, and epitope mapping. Full-length human PVRIG in Synthetic Nanodisc and Strep-tagged formats supports binding in a membrane context and membrane-proximal epitope studies. ELISA/flow cytometry-validated chimeric monoclonal antibodies, reference antibodies, and PE/biotin formats support cell-surface detection and candidate benchmarking. RAJI DiSliceX™ tissue slides provide an additional IHC research tool. DIMA also maintains a PVRIG single B-cell seed library and lead-antibody resources.